APA (7th ed.) Citation

Salles, G., Długosz-Danecka, M., Ghesquières, H., & Jurczak, W. (2021). Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma. Expert opinion on biological therapy, 21(4), 455-463. https://doi.org/10.1080/14712598.2021.1884677

Chicago Style (17th ed.) Citation

Salles, Gilles, Monika Długosz-Danecka, Hervé Ghesquières, and Wojciech Jurczak. "Tafasitamab for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma." Expert Opinion on Biological Therapy 21, no. 4 (2021): 455-463. https://doi.org/10.1080/14712598.2021.1884677.

MLA (9th ed.) Citation

Salles, Gilles, et al. "Tafasitamab for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma." Expert Opinion on Biological Therapy, vol. 21, no. 4, 2021, pp. 455-463, https://doi.org/10.1080/14712598.2021.1884677.